Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

uniQure N.V. (QURE)

22.82   -0.1 (-0.44%) 02-08 09:41
Open: 22.9 Pre. Close: 22.92
High: 22.9 Low: 22.7
Volume: 9,963 Market Cap: 1,068(M)

Technical analysis

as of: 2023-02-07 4:31:16 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 27.4     One year: 32
Support: Support1: 21.74    Support2: 20.69
Resistance: Resistance1: 23.45    Resistance2: 27.4
Pivot: 21.74
Moving Average: MA(5): 22.38     MA(20): 21.83
MA(100): 21.27     MA(250): 19.35
MACD: MACD(12,26): -0.1     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 70.9     %D(3): 62.8
RSI: RSI(14): 56.9
52-week: High: 28.25  Low: 12.52
Average Vol(K): 3-Month: 697 (K)  10-Days: 417 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ QURE ] has closed Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 23.02 - 23.11 23.11 - 23.19
Low: 22.09 - 22.2 22.2 - 22.3
Close: 22.72 - 22.91 22.91 - 23.07

Company Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Headline News

Wed, 08 Feb 2023
Rising Trends of Telehealth Market will Witness Substantial Growth ... - Digital Journal

Tue, 07 Feb 2023
Feedback encouraged by interest in Bleepa and Carelocker in NHS ... - Proactive Investors UK

Thu, 02 Feb 2023
Barclays PLC Purchases 129286 Shares of uniQure (NASDAQ:QURE) - MarketBeat

Tue, 31 Jan 2023
Health Care Sector Update for 01/31/2023: HILS, QURE, SILO - Nasdaq

Tue, 31 Jan 2023
QURE stock gains as uniQure inks licensing deal for ALS candidate ... - Seeking Alpha

Fri, 20 Jan 2023
Paula Soteropoulos Sells 6000 Shares of uniQure (NASDAQ:QURE ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 46 (M)
Shares Float 35 (M)
% Held by Insiders 7 (%)
% Held by Institutions 91.3 (%)
Shares Short 3,000 (K)
Shares Short P.Month 2,960 (K)

Stock Financials

EPS -2.81
EPS Est Next Qtl -0.7
EPS Est This Year -2.98
EPS Est Next Year -2.66
Book Value (p.s.) 5.44
Profit Margin (%) -184.1
Operating Margin (%) -235.6
Return on Assets (ttm) -12.3
Return on Equity (ttm) -20.4
Qtrly Rev. Growth -100
Gross Profit (p.s.) 7.83
Sales Per Share 1.34
EBITDA (p.s.) -3
Qtrly Earnings Growth 0
Operating Cash Flow -129 (M)
Levered Free Cash Flow -86 (M)

Stock Valuations

PE Ratio -8.16
PEG Ratio 0
Price to Book value 4.2
Price to Sales 17.09
Price to Cash Flow -8.24

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.